A Phase IIb Open-label, Multi-centre, Extension Study to Explore the Long-term Safety and Efficacy of KH176 in Subjects With a Genetically Confirmed Mitochondrial DNA tRNALeu(UUR) m.3243A>G Mutation Who Have Completed the KHENERGYZE Study KH176-202
Latest Information Update: 13 Mar 2024
At a glance
- Drugs Sonlicromanol (Primary)
- Indications Mitochondrial disorders
- Focus Adverse reactions
- Acronyms KHENEREXT; The KHENEREXT Study
- Sponsors Khondrion
- 04 Sep 2023 This trial has been completed in Denmark, according to European Clinical Trials Database record.
- 07 Mar 2023 Planned End Date changed from 1 Mar 2023 to 1 Sep 2023.
- 07 Mar 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Sep 2023.